



[Go to Product page](#)

Datasheet for ABIN6253337

Interleukin 35 Protein (IL35) (AA 21-229, AA 57-253) (Fc Tag)

Overview

Quantity:	25 µg
Target:	Interleukin 35 (IL35)
Protein Characteristics:	AA 21-229, AA 57-253
Origin:	Human
Source:	CHO Cells
Protein Type:	Recombinant
Purification tag / Conjugate:	This Interleukin 35 protein is labelled with Fc Tag.

Product Details

Purpose:	IL-35 (human):Fc (human) (rec.)
Specificity:	The human IL-35 complex composed of the Ebi3 subunit (aa 21-229) and the IL-12a (p35) subunit (aa 57-253) is fused through a polypeptide linker to the Fc portion of human IgG1.
Characteristics:	<p>Protein. The human IL-35 complex composed of the Ebi3 subunit (aa 21-229) and the IL-12a (p35) subunit (aa 57-253) is fused through a polypeptide linker to the Fc portion of human IgG1.</p> <p>Source: CHO cells. Endotoxin content: <0.06EU/µg protein (LAL test, Lonza). Lyophilized from 0.2µm-filtered solution in PBS. Purity: >98 % (SDS-PAGE). Interleukin-35 (IL-35) is a novel IL-12 family cytokine produced by regulatory T cells (Treg) but not by resting or activated effector T cells (Teff). IL-35 is a heterodimeric protein composed of EBI3 (Epstein-Barr-Virus-induced gene 3) and IL-12a (p35). EBI3 is a downstream target of Foxp3, a transcription factor required for Treg-cell development and function, and thus Treg-cell restriction of IL35 occurs. Regulatory T cells are essential for maintaining self tolerance and preventing autoimmunity, and IL-35 is identified as a molecule that mediates the immune suppression function of Treg-cell. As an</p>

Product Details

inhibitory cytokine, IL-35 induces proliferation of Treg-cell populations but suppresses Th17 cell development. Studies in mice show the absence of either IL-35 chain from Treg-cell reduces the cells' ability to suppress inflammation using an experimental model for inflammatory bowel disease. IL-35 is suggested as a potential target of immunotherapy.

Purity: >98 % (SDS-PAGE)

Endotoxin Level: <0.06EU/μg protein (LAL test, Lonza).

Biological Activity Comment: Bioactivity was measured in a cell proliferation assay using anti-CD3 activated human peripheral mononuclear cells.

Target Details

Target: Interleukin 35 (IL35)

Alternative Name: IL-35 ([IL35 Products](#))

Background: Alternate Names/Synonyms: Interleukin-35

Product Description: Interleukin-35 (IL-35) is a novel IL-12 family cytokine produced by regulatory T cells (Treg) but not by resting or activated effector T cells (Teff). IL-35 is a heterodimeric protein composed of EBI3 (Epstein-Barr-Virus-induced gene 3) and IL-12a (p35). EBI3 is a downstream target of Foxp3, a transcription factor required for Treg-cell development and function, and thus Treg-cell restriction of IL35 occurs. Regulatory T cells are essential for maintaining self tolerance and preventing autoimmunity, and IL-35 is identified as a molecule that mediates the immune suppression function of Treg-cell. As an inhibitory cytokine, IL-35 induces proliferation of Treg-cell populations but suppresses Th17 cell development. Studies in mice show the absence of either IL-35 chain from Treg-cell reduces the cells' ability to suppress inflammation using an experimental model for inflammatory bowel disease. IL-35 is suggested as a potential target of immunotherapy.

NCBI Accession: [NP_000873](#)

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Concentration: Lot specific

Handling

Buffer:	Lyophilized from 0.2µm-filtered solution in PBS.
Handling Advice:	Avoid freeze/thaw cycles.
Storage:	4 °C,-20 °C
Storage Comment:	Short Term Storage: +4°C Long Term Storage: -20°C Use & Stability: Stable for at least 1 year after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C.